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Introduction
The availability of methotrexate (MTX) and biological
agents has provided a major change in the treatment
of children with juvenile idiopathic arthritis (JIA). An
international registry named Pharmachild (European
Union grant 260353) has been set up by the Pediatric
Rheumatology International Trials Organisation
(PRINTO)/Pediatric Rheumatology European Society
(PRES). In parallel several national registries with the
same purpose have been set up in different European
Countries for the follow-up of these patients.
Objectives
To evaluate the possibility to combine data coming from
different national registries in order to assess the long-term
safety.
Methods
We merged into a unified database the baseline demo-
graphic data of JIA patients treated with MTX or biolo-
gicals coming from the Pharmachild registry and from
the national registries of Germany, United Kindgom and
Portugal. Data are presented as frequencies (%) or med-
ians with 1st and 3rd quartiles.
Results
About 63% of the patients has been treated with biologi-
cals alone or in combination with MTX, and 29% only
with MTX. The events of special interest (ESI) ranged
from 4.5 to 15.0% and the other moderate/severe/serious
adverse events (AE) from 13.1% to 69.9%. Table 1.
Conclusion
Combination of information from different data sources is
a recommended task and will provide a powerful tool for
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Age at onset 5.4 (2.4 – 10.0) - 7.2 (3.1-11.4) 6.3 (2.5-10.9) -
Age at JIA Diagnosis 6.2 (2.8 – 11.0) 5.5 (2.1-10.2) 8.2 (4.0-12.3) 7.3 (3.3-12.3) -
Disease duration at the last follow-up 4.9 (2.5 – 8.2) 5.4 (2.7 – 8.8) 5.2 (3.1-8.4) 3.0 (0.5-9.6) -
Therapy with MTX only 1365 (24.5) 503 (32.7) 1132/3134 (36.1) 0 (0.0) 3000/10354
(29.0)
Therapy with only one Biologic Drug +
MTX
2378 (42.7) 862 (56.1) 1545/3134 (49.2) 27 (24.1) 4812/10354
(46.5)
Therapy with more than one Biologic +
MTX
872 (15.6) 141 (9.2) 340/3134 (10.8) 78 (69.6) 1431/10354
(13.8)
Nr. patients with ESI or AE 1070 (19.2) 1093 (71.1) 1163(37.1) 27 (24.1) 3353 (32.4)
Nr. patients with ESI 496 (8.9) 230 (15.0) 249 (7.9) 5 (4.5) 980 (9.5)
Nr. patients with AE 729 (13.1) 1075 (69.9) 1069 (34.1) 24 (21.4) 2897 (28.0)
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